🔷 These results support the growing role of immunotherapy-based combinations in earlier hepatocellular carcinoma treatment. Integrating systemic and locoregional therapies may help improve patient outcomes.
🔗 Read more: bit.ly/ONCOnews-07-...
#ONCOnews #OncoAlert #OncEd #LiverCancer #Astrazeneca
🚨 Latest #Phase 3 Trial Update!
🔷 The Phase III EMERALD-3 trial showed that Imfinzi® plus Imjudo® with Lenvatinib and TACE greatly improved progression-free survival in embolisation-eligible unresectable liver cancer. This multi-modal approach shows enhanced disease control and delayed progression.
✅️ Apply trial evidence to real-world decision-making
✅️ Recognise resistance mechanisms and optimise next-line systemic strategies
#Oncology #CancerCare #MedicalEducation #Healthcare #MedEd #ClinicalEducation #MedicalLearning #CancerResearch #SkinCancer #BasalCellCarcinoma #Dermatology
👉️ Take the Basal Cell Carcinoma quiz now - bit.ly/BCCA_ONCO_IQ_X
This peer-reviewed ONCO-IQ quiz is designed for oncology professionals—a fast, high-yield knowledge check you can complete in minutes.
✅️ Navigate treatment sequencing in locally advanced and HHI-refractory BCC
🔷 The decision is supported by clinical evidence demonstrating meaningful benefit in a difficult-to-treat setting. The combination highlights continued progress toward improving outcomes in recurrent ovarian cancer through immunotherapy-based strategies.
🔗 Read more: bit.ly/ONCOnews-06_...
🚨 Latest #Oncology Update!
🔷 The European Commission has approved KEYTRUDA in combination with Paclitaxel ± Bevacizumab for adults with PD-L1 (CPS ≥1) platinum-resistant recurrent ovarian carcinoma. This approval gives treatment options for patients who have received one or systemic therapies.
✅️ Understand how ESR1 ligand-binding domain mutations drive endocrine resistance
✅️ Interpret clinical prevalence and impact on treatment outcomes in ER+/HER2– advanced breast cancer
✅️ Apply genomic insights to real-world therapeutic decision-making
#Oncology #BreastCancer #PrecisionMedicine
This post is not intended for the U.S. audience.
👉️ Take the ESR1 Mutations: Relevance in Breast Cancer & Potential Therapeutic Implications now - bit.ly/ESR1_ONCO_IQ_X
This peer-reviewed ONCO-IQ quiz is designed for oncology professionals—a fast, high-yield knowledge check you can finish in mins
🔷 This highlights the growing role of real-world evidence in precision oncology, enabling broader application of HER2-directed therapy across tumor types and informing regulatory decisions in biomarker-defined populations.
🔗 Read more: bit.ly/ONCOnews-31-...
#ONCOnews #OncoAlert #OncEd #Oncology
🚨 Latest #Oncology Update!
🔷 Real-world evidence generated using Guardant Health’s InfinityAI platform supported the approval of ENHERTU® (Trastuzumab deruxtecan) in Japan for previously treated HER2-positive advanced solid tumors, complementing data from DESTINY clinical trials.
✅️ Understand how ESR1 ligand-binding domain mutations drive endocrine resistance
✅️ Interpret clinical prevalence and impact on treatment outcomes in ER+/HER2– advanced breast cancer
✅️ Apply genomic insights to real-world therapeutic decision-making
#Oncology #BreastCancer #PrecisionMedicine
This post is not intended for the U.S. audience.
👉️ Take the ESR1 Mutations: Relevance in Breast Cancer & Potential Therapeutic Implications now - bit.ly/ESR1_ONCO_IQ_X
This peer-reviewed ONCO-IQ quiz is designed for oncology professionals a fast, high-yield knowledge check you can finish in mins
🔷 Tarlatamab offers a novel treatment approach for patients with limited options in the relapsed ES-SCLC setting. The positive opinion highlights continued progress in expanding targeted therapies for aggressive lung cancers.
🔗 Read more: bit.ly/ONCOnews-30-...
#ONCOnews #OncoAlert #OncEd
🚨 Latest #Oncology Update!
🔷 EMA has recommended Imdylltra (tarlatamab) for relapsed ES-SCLC after platinum therapy. Phase 3 data showed improved OS of 13.6 vs 8.3 months, reducing risk of death by 40%.
🔷 The approval strengthens precision oncology by supporting more personalized treatment decisions in upper gastrointestinal cancers. PD-L1 testing remains a key tool in optimizing therapy selection and improving clinical outcomes.
🔗 Read more: bit.ly/ONCOnews-23-...
#ONCOnews #OncoAlert #OncEd
🚨 Latest #FDA Update!
🔷 The FDA has approved PD-L1 IHC 22C3 pharmDx as a companion diagnostic for patients with esophageal and gastroesophageal junction (GEJ) carcinoma, enabling identification of patients with PD-L1 CPS ≥1 who may benefit from pembrolizumab.
🔷 Relacorilant, a selective glucocorticoid receptor antagonist, enhances chemotherapy activity through cortisol pathway modulation, offering a promising new approach for patients with limited therapeutic alternatives.
🔗 Read more: bit.ly/ONCOnews-27M...
#ONCOnews #OncoAlert #OncEd #FDAApproval
🔷 Approval was based on the Phase 3 ROSELLA trial, where the combination improved overall survival (16.0 vs 11.9 months; HR 0.65) and progression-free survival (HR 0.70) versus chemotherapy alone.
🚨 Latest #FDA Update!
🔷 The FDA has approved Lifyorli™ (Relacorilant) in combination with Nab-paclitaxel for patients with platinum-resistant ovarian cancer, introducing a novel treatment option in a difficult-to-treat setting.
🔷 Fast Track status may support expedited development and regulatory review of TRI-611. This milestone reflects continued progress in expanding targeted therapy options for patients with ALK-driven tumors.
🔗 Read more: bit.ly/ONCOnews-26-...
#ONCOnews #OncoAlert #OncEd #LungCancer #NSCLC
🔷 TRI-611 is an oral, brain-penetrant molecular glue degrader designed to target and eliminate ALK fusion proteins.
🚨 Latest #FDA Update!
🔷 TRIANA Biomedicines’ TRI-611 has received U.S. FDA Fast Track designation for the treatment of ALK-positive non-small cell lung cancer. The designation highlights the therapy’s potential to address an unmet need in targeted lung cancer treatment.
🔷 Secondary outcomes included testosterone suppression, overall survival, and safety, with tE2 showing similar castration rates and fewer hot flashes but higher gynecomastia, supporting its potential as an alternative hormonal therapy option.
🔗 Read more: bit.ly/ONCOnews-26-...
#ONCOnews #Onco
🚨 Latest #Phase 3 Update!
🔷 A Phase 3 randomized trial compared transdermal estradiol (tE2) patches with LHRH agonists in men with locally advanced prostate cancer. The study showed comparable 3-year metastasis-free survival (87.1% vs 85.9%; HR 0.96), meeting the predefined non-inferiority margin.
🔷 The combination significantly improved 3-year DFS (86.3% vs 76.2%; HR 0.50; P<0.001), with higher grade 3–4 adverse events (84.1% vs 71.9%); overall survival remains a secondary endpoint under evaluation.
🔗 Read more: bit.ly/ONCOnews-26-...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerResearch
🚨 Latest #Phase3 Update!
🔷 A Phase 3 trial evaluated adjuvant Atezolizumab plus mFOLFOX6 in patients with resected stage III dMMR colon cancer, compared with mFOLFOX6 alone. The study assessed whether adding immunotherapy could enhance disease-free survival (DFS) outcomes.
🔷 Orphan Drug Designation supports accelerated development in high unmet-need settings, underscoring growing interest in targeted ADC approaches to improve outcomes in this aggressive malignancy.
🔗 Read more: bit.ly/ONCOnews-25-...
#ONCOnews #OncoAlert #OncEd #Oncology #CancerResearch #LungCancer
🚨 Latest #Oncology Update!
🔷 GSK plc’s investigational B7-H3-targeted antibody-drug conjugate, Risvutatug rezetecan, has received Orphan Drug Designation in Japan for the treatment of Small-Cell Lung Cancer, supported by phase 1 ARTEMIS-001 trial.
🔷 Phase 3 SWOG 1826 data showed significantly improved progression-free survival with nivolumab + AVD (HR 0.42; 58% risk reduction), supporting its role in advancing long-term disease control.
🔗 Read more: bit.ly/ONCOnews-24M...
#ONCOnews #OncoAlert #OncEd #Oncology #Hematology #HodgkinLymphoma
🚨 Latest #Approval Update!
🔷 Bristol Myers Squibb has gained expanded U.S. and EU approvals for Opdivo® (nivolumab) in classical Hodgkin lymphoma. New indications include nivolumab-based combinations for both previously untreated and relapsed/refractory patients.
